Pharmacological treatment of heart failure.
This article provides an overview of heart failure (HF) and pharmacological treatment of systolic left ventricular dysfunction. The purpose of this article is to provide nurses the knowledge of current treatment recommendations and the Five Million Lives campaign sponsored by the National Institute of Healthcare Improvement. This initiative is a national campaign to protect 5 million patients from medical harm by promoting evidence-based standards of practice to improve the healthcare of Americans. HF has become part of this national initiative and the National Institute of Healthcare Improvement in conjunction with the American College of Cardiology/American Heart Association has implemented guidelines to improve the care of HF patients. Nurses would be expected to be familiar with these guidelines, as regulatory agencies will be using these guidelines as a benchmark to evaluate the quality of care provided to patients with this diagnosis.
Quinn
Beverly
B
Scripps Memorial Hospital Encinitas, Encinitas, California 92024, USA. Bevquinn1@sbcglobal.net
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000804:Angiotensin II / Q000037:antagonists & inhibitors; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D019985:Benchmarking; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D002316:Cardiotonic Agents / Q000627:therapeutic use; D003422:Critical Care / Q000458:organization & administration*; D004232:Diuretics / Q000627:therapeutic use; D019317:Evidence-Based Medicine; D006287:Health Planning Guidelines; D054143:Heart Failure, Systolic / Q000188:drug therapy / Q000209:etiology* / Q000451:nursing*; D006801:Humans; D000451:Mineralocorticoid Receptor Antagonists / Q000627:therapeutic use; D024802:Nurse's Role; D017410:Practice Guidelines as Topic; D019984:Quality Indicators, Health Care; D017749:Total Quality Management; D014665:Vasodilator Agents / Q000627:therapeutic use; D018487:Ventricular Dysfunction, Left / Q000150:complications*
D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D002121:Calcium Channel Blockers; D002316:Cardiotonic Agents; D004232:Diuretics; D000451:Mineralocorticoid Receptor Antagonists; D014665:Vasodilator Agents; D000804:Angiotensin II